China’s 1st Digital Therapeutical Products for Tumor Approved

Recently, the subsidiary of TEDA-base LinkDoc Technologies got the first certificate of digital therapeutics for tumor in China, and its digital therapeutical product, TH-002, was approved for marketing. Based on LinkDoc’s tumor big data platform and AI technology, the product will provide personal out-of-hospital rehabilitation for patients with early postoperative lung cancer.

LinkDoc is a medical technology enterprise driven by data and empowered by AI. Committed to major diseases such as tumor and rare diseases, the company provides big data one-stop solution. Landed in TEDA in 2016, the business of the company is now covering 31 provinces, autonomous regions and municipalities.